Controversies in palivizumab use.
Stevens
Timothy P
TP
Golisano Children's Hospital at Strong, University of Rochester Medical Center, Rochester, NY, USA.
Hall
Caroline B
CB
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics*; D061067:Antibodies, Monoclonal, Humanized; D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy / Q000517:prevention & control; D002675:Child, Preschool; D002908:Chronic Disease; D003362:Cost-Benefit Analysis; D003428:Cross Infection / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D015278:Intensive Care Units, Pediatric; D008297:Male; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000517:prevention & control; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069455:Palivizumab